CDC Tracks Highly Mutated BA.3.2 COVID Variant in 25 US States
United States

PATRICK T. FALLON/AFP via Getty Images/Getty
Source Analysis
What Happened
Why It Matters
What Happened
Why It Matters
Where Sources Agree
- arrows_inputUS Variant Detection Confirmed: Sources align on the BA.3.2 variant's detection in 25 U.S. states, noting its initial identification in the U.S. occurred in June 2025, according to CDC and WHO reports.
- arrows_inputNew Variant Evades Immunity: Sources across outlets confirm the BA.3.2 Omicron descendant carries 70 to 75 genetic changes in its spike protein, which may reduce protection from current vaccines targeting JN.1 subvariants, according to CDC analysis and laboratory studies.
- arrows_inputBA.3.2 Severity Unchanged: Predominant reporting shows the BA.3.2 variant causes symptoms similar to other Omicron strains and does not appear to cause more severe illness; all hospitalized patients with the variant survived, according to CDC analysis and reported cases.
Where Sources Disagree
- arrows_outputBA.3.2 Threat Assessment: Some sources indicate the BA.3.2 variant is not currently dominant or causing more severe illness. However, other sources suggest its mutations carry high risk potential and could drive a summer surge.
- arrows_outputBA.3.2 Vaccine Effectiveness: Some health organizations expect current vaccines to protect against severe disease from the BA.3.2 variant. However, other researchers suggest current vaccines may not protect against infection or evade immunity.
Timeline
March 19, 2026
CDC tracking and recent data: The CDC reported on March 19, 2026 that it was tracking BA.3.2 after routine surveillance detected a steady rise in U.S. cases, while WasteWaterSCAN data showed BA.3.2 in 3.7% of wastewater samples as of March 14, 2026, reflecting active monitoring and mixed signals about prevalence.
February 11, 2026
Widespread U.S. detections: By February 11, 2026, CDC data showed BA.3.2 present in clinical samples from five patients, nasal swabs from four travelers, three airplane wastewater samples and 132 wastewater samples across 25 U.S. states, indicating broader circulation than clinical sequencing alone revealed.
December 5, 2025
WHO monitoring, lab concerns: The World Health Organization designated BA.3.2 a Variant Under Monitoring on December 5, 2025, while lab studies found roughly 70–75 spike protein mutations and reduced antibody neutralization by the 2025–2026 LP.8.1-adapted mRNA vaccine in laboratory tests. These findings raised concern about potential immune evasion and the need for more data on vaccine effectiveness.
Summary by Ground AI
Sources
See All 60A varied selection of sources chosen by Ground to reflect the diversity of this story’s coverage.
Most Written About
The stories getting the most coverage from the last 24 hours
Source Analysis
Timeline
March 19, 2026
CDC tracking and recent data: The CDC reported on March 19, 2026 that it was tracking BA.3.2 after routine surveillance detected a steady rise in U.S. cases, while WasteWaterSCAN data showed BA.3.2 in 3.7% of wastewater samples as of March 14, 2026, reflecting active monitoring and mixed signals about prevalence.
February 11, 2026
Widespread U.S. detections: By February 11, 2026, CDC data showed BA.3.2 present in clinical samples from five patients, nasal swabs from four travelers, three airplane wastewater samples and 132 wastewater samples across 25 U.S. states, indicating broader circulation than clinical sequencing alone revealed.
December 5, 2025
WHO monitoring, lab concerns: The World Health Organization designated BA.3.2 a Variant Under Monitoring on December 5, 2025, while lab studies found roughly 70–75 spike protein mutations and reduced antibody neutralization by the 2025–2026 LP.8.1-adapted mRNA vaccine in laboratory tests. These findings raised concern about potential immune evasion and the need for more data on vaccine effectiveness.












